CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 338 enrolled
Drug / intervention
Semaglutide +3 moredrug
Likely dose
Semaglutide 2.4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04074161
NCT04074161Phase 3Completed

Effect and Safety of Subcutaneous Semaglutide 2.4 mg Once Weekly Compared to Liraglutide 3.0 mg Once Daily on Weight Management in Subjects With Overweight or Obesity

Novo Nordisk A/S·interventional·Posted Aug 29, 2019·Updated May 19, 2023

In Brief

A Phase 3 clinical trial evaluating Semaglutide, Placebo (semaglutide), and 2 other interventions for Overweight and Obesity. Completed, enrolled 338 participants across 19 sites.

Detailed Summary

This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years. This is to compare the effect on body weight in people taking semaglutide once a week or people taking liraglutide once every day. Participants will either get semaglutide, liraglutide or "dummy" medicine. Which treatment is decided by chance. Participants who receive semaglutide or semaglutide "dummy" medicine will need to take 1 injection once a week. Participants who receive liraglutide or liraglutide "dummy" medicine will need to take 1 injection once daily. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. During the study participants will have talks with study staff about eating healthy food and how to be more physically active. Participants will have 16 clinic visits and 7 phone calls with the study doctor. At 4 of the clinic visits participants cannot eat and drink (water is allowed) for 8 hours before the visit. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOverweight, Obesity
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedAug 29, 2019
Enrollment StartSep 11, 2019
Primary CompletionMar 27, 2021
Study CompletionMay 11, 2021
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.8 years ago

Interventions

Semaglutidedrug

Dose gradually increased to 2.4 mg administered once weekly for 68 weeks

Placebo (semaglutide)drug

Administered once weekly for 68 weeks

Liraglutidedrug

Dose gradually increased to 3.0 mg administered once daily for 68 weeks

Placebo (liraglutide)drug

Administered once daily for 68 weeks